Cargando…
Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine
BACKGROUND: Cyclic guanosine monophosphate‐protein kinase G‐phosphodiesterase 5 signaling may be disturbed in heart failure (HF) with preserved ejection fraction, contributing to cardiac remodeling and dysfunction. The purpose of this study was to manipulate cyclic guanosine monophosphate signaling...
Autores principales: | Hiemstra, Jessica A., Lee, Dong I., Chakir, Khalid, Gutiérrez‐Aguilar, Manuel, Marshall, Kurt D., Zgoda, Pamela J., Cruz Rivera, Noelany, Dozier, Daniel G., Ferguson, Brian S., Heublein, Denise M., Burnett, John C., Scherf, Carolin, Ivey, Jan R., Minervini, Gianmaria, McDonald, Kerry S., Baines, Christopher P., Krenz, Maike, Domeier, Timothy L., Emter, Craig A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843537/ https://www.ncbi.nlm.nih.gov/pubmed/27098966 http://dx.doi.org/10.1161/JAHA.116.003277 |
Ejemplares similares
-
Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux
por: Subbotina, Anna, et al.
Publicado: (2017) -
Hirudin promotes proliferation and osteogenic differentiation of HBMSCs via activation of cyclic guanosine monophosphate (cGMP)/protein kinase-G (PKG) signaling pathway
por: Cao, Shun, et al.
Publicado: (2022) -
A new twist on an old idea part 2: cyclosporine preserves normal mitochondrial but not cardiomyocyte function in mini‐swine with compensated heart failure
por: Hiemstra, Jessica A., et al.
Publicado: (2014) -
Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells
por: Li, Dapeng, et al.
Publicado: (2018) -
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)